Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies

A Review of Nice Technology Appraisals in Oncology Using Single Arm Trials (SAT) Evidence

(2018) D Alexiou et al.   VALUE IN HEALTH

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

(2018) Charles S. Fuchs et al.   JAMA Oncology

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Yoon-Koo Kang et al.   LANCET

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

(2017) Thomas Powles et al.   JAMA Oncology

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

(2016) Stéphane Champiat et al.   CLINICAL CANCER RESEARCH

Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014

(2016) Anthony J Hatswell et al.   BMJ Open

Simulation and Matching-Based Approaches for Indirect Comparison of Treatments

(2015) K. Jack Ishak et al.   PHARMACOECONOMICS

Bias in progression-free survival analysis due to intermittent assessment of progression

(2015) Leilei Zeng et al.   STATISTICS IN MEDICINE

Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer

(2012) Yingwei Qi et al.   CANCER

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials

(2011) James E. Signorovitch et al.   CURRENT MEDICAL RESEARCH AND OPINION

Proportional hazards regression with interval censored data using an inverse probability weight

(2010) Glenn Heller   LIFETIME DATA ANALYSIS